Inflammatory Bowel Diseases
Recent clinical, regulatory, research and industry developments relating to this disease.
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation.
Implications of gut microbiota-mediated epigenetic modifications in intestinal diseases.
Microbes with higher metabolic independence are enriched in human gut microbiomes under stress.
Gut Microbiota Serves as a Crucial Independent Biomarker in Inflammatory Bowel Disease (IBD).
The Gut Microbiome Advances Precision Medicine and Diagnostics for Inflammatory Bowel Diseases.
Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies.
Revolutionizing immune research with organoid-based co-culture and chip systems.
A Comprehensive Review of the Triangular Relationship among Diet-Gut Microbiota-Inflammation.
The emerging role of the gut microbiota and its application in inflammatory bowel disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel Disease
- Q4 2027Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life Data
- Q3 2028A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)
Clinical MilestonesViewHide
- 2026-07-20A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)Results expected Q3 2028
- 2026-06-25Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life DataResults expected Q4 2027
- 2026-03-13Activation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel DiseaseResults expected Q3 2027
- 2026-05-01Subcutaneous Infliximab After A Previous Intravenous Dose OptimizationPrimary completion
- 2025-09-20Clinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative ColitisCompleted
- 2027-09-01ClinicalImmunogenicity and Safety of the Adjuvanted Recombinant Zoster Vaccine in Adults with Inflammatory Bowel Disease on Biologic Immunosuppressive TherapiesWithdrawn
- 2026-07-20ClinicalA Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Crohn's Disease (GARNET)Results expected Q3 2028
- 2026-06-25ClinicalDigestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Was Switched to Ustekinumab Due to Paradoxical Psoriasis: Real Life DataResults expected Q4 2027
- 2026-05-01ClinicalSubcutaneous Infliximab After A Previous Intravenous Dose OptimizationPrimary completion
- 2026-03-13ClinicalActivation of Autophagy and Suppression of Apoptosis by Dapagliflozin Attenuates Inflammatory Bowel DiseaseResults expected Q3 2027
- 2025-09-20ClinicalClinical Study to Evaluate the Possible Efficacy of Fenofibrate in Patient With Ulcerative ColitisCompleted
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Jayempi is indicated in combination with other immunosuppressive agents for the prophylax… (2021)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Inflammatory Bowel Diseases35
- Gastrointestinal Microbiome25
- Microbiota8
- Colitis5
- Colitis, Ulcerative5
- Crohn Disease4
- Diet4
- Homeostasis4
Leading journals6
- Frontiers in immunology8
- International journal of molecular sciences8
- Gut5
- Nature communications4
- Nutrients4
- EBioMedicine3
Leading researchers8
- Liu Y3
- Armuzzi A2
- Bergen SE2
- Butterworth AS2
- Cammarota G2
- Danese S2
- Danesh J2
- Deleu S2
Affiliations (unnormalised)6
- Imperial College London5
- University of Cambridge4
- School of Medicine3
- University Medical Center Groningen3
- Wellcome Sanger Institute3
- Biomedical Center2
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Inflammatory bowel diseases are chronic, non-specific inflammatory disorders of the gastrointestinal tract. The term includes Crohn disease and ulcerative colitis. The literature describes them as heterogeneous conditions involving clinical, immunological, molecular, genetic, and microbial variation.
The etiology is described as multifactorial, with genetic and environmental contributions. Review abstracts also describe a complex interplay between genetic, immunologic, microbial, and environmental factors. Dysbiosis of the gut microbiome is increasingly considered causally related to inflammatory bowel diseases.
The disease is associated with disturbed host-microbe interactions and functional dysbiosis in the gut microbiome. Literature highlights reduced short-chain fatty acid-producing bacteria and reduced fecal short-chain fatty acids in active disease, alongside impaired intestinal homeostasis and barrier function. Reviews also emphasize roles for innate immunity, cytokines, interleukin-23, mucins, and intestinal permeability in the inflammatory process.
Environmental factors are implicated in disease risk, and dysbiosis of the gut microbiome is described as causally related. A Western lifestyle is noted as strongly affecting the microbiome changes associated with inflammatory bowel diseases. Genetic factors are also part of the risk background described in the supplied material.
The supplied grounding supports treatment at the modality level rather than specific regimens. Literature coverage includes therapy and drug therapy, and the co-studied dextran sulfate indicates use in experimental or model contexts rather than standard treatment. The review abstracts also discuss microbiota-directed approaches such as probiotics and manipulation of gut microbiota, but no definitive standard drug-class treatment is specified in the grounding.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.